Yasuhiro Nakashima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yasuhiro Nakashima has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
Hideo Koh
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
15 shared publications- Hirohisa Nakamae
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
15 shared publications Masayuki Hino
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
15 shared publications- Mitsutaka Nishimoto
Department of Hematology Osaka Metropolitan University Graduate School of Medicine Osaka Japan
10 shared publications Teruhito Takakuwa
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
10 shared publications- Hiroshi Okamura
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
9 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4427-4438
Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis
Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4427-4438
Open AccessDrivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis
Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.
- 14 February 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (4) , 492-495
Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy
- 14 February 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (4) , 492-495
Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy
- Open Access
- 28 January 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (1)
Older patients with LBCL show comparable outcomes to younger patients and product-specific profiles in CAR-T therapy
- 28 January 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (1)
Open AccessOlder patients with LBCL show comparable outcomes to younger patients and product-specific profiles in CAR-T therapy
- 24 December 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (3) , 102042
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry
- 24 December 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (3) , 102042
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry
- 26 August 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (11) , 1628-1630
Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation
- 26 August 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (11) , 1628-1630
Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation
- 4 July 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (12) , e440-e441
A case of alopecia areata multiplex accompanied by chronic idiopathic thrombocytopenic purpura
- 4 July 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (12) , e440-e441
A case of alopecia areata multiplex accompanied by chronic idiopathic thrombocytopenic purpura
- Open Access
- 14 May 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
- 14 May 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
Open AccessT cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
- 14 February 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (5) , 695-698
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma
- 14 February 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (5) , 695-698
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma